The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to
the Securities and Exchange Commission (SEC)
by insider Hoberman Kenneth since year 2005.
The trader's CIK number is 1573722.
At the time of the last reporting, Hoberman Kenneth was the Chief Operating Officer of Stemline Therapeutics Inc .
(stock ticker symbol STML).
See this page for all insider trading activities at Stemline Therapeutics Inc .
| Trade Date | Symbol | Company Name (Issuer) | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|---|
| 2019-06-26 | STML | Stemline Therapeutics Inc | Sale | 12,508 | 14.77 | 184,743 |
| 2019-06-24 | STML | Stemline Therapeutics Inc | Sale | 9,107 | 15.49 | 141,067 |
| 2019-06-25 | STML | Stemline Therapeutics Inc | Sale | 25,500 | 15.07 | 384,285 |
| 2019-05-14 | STML | Stemline Therapeutics Inc | Sale | 25,817 | 14.27 | 368,408 |
| 2019-03-12 | STML | Stemline Therapeutics Inc | Sale | 981 | 11.04 | 10,830 |
| 2019-03-11 | STML | Stemline Therapeutics Inc | Sale | 25,101 | 11.11 | 278,872 |
| 2019-03-07 | STML | Stemline Therapeutics Inc | Sale | 2,995 | 11.36 | 34,023 |
| 2019-02-25 | STML | Stemline Therapeutics Inc | Sale | 10,557 | 12.05 | 127,211 |
| 2019-01-08 | STML | Stemline Therapeutics Inc | Sale | 13,547 | 10.15 | 137,502 |
| 2018-11-26 | STML | Stemline Therapeutics Inc | Sale | 26,296 | 11.85 | 311,607 |
| 2018-03-12 | STML | Stemline Therapeutics Inc | Sale | 17,241 | 17.71 | 305,338 |
| 2018-03-13 | STML | Stemline Therapeutics Inc | Sale | 12,746 | 16.82 | 214,387 |
| 2018-03-07 | STML | Stemline Therapeutics Inc | Sale | 3,027 | 16.55 | 50,096 |
| 2018-02-26 | STML | Stemline Therapeutics Inc | Sale | 5,300 | 17.61 | 93,333 |
| 2018-02-27 | STML | Stemline Therapeutics Inc | Sale | 5,726 | 17.26 | 98,830 |
| 2018-02-15 | STML | Stemline Therapeutics Inc | Sale | 1,851 | 15.67 | 29,005 |
| 2018-01-08 | STML | Stemline Therapeutics Inc | Sale | 14,040 | 13.93 | 195,577 |
| 2017-12-15 | STML | Stemline Therapeutics Inc | Sale | 11,943 | 14.18 | 169,351 |
| 2017-12-18 | STML | Stemline Therapeutics Inc | Sale | 40 | 14.75 | 590 |
| 2017-03-07 | STML | Stemline Therapeutics Inc | Sale | 2,342 | 8.16 | 19,110 |
| 2017-02-27 | STML | Stemline Therapeutics Inc | Sale | 4,000 | 6.97 | 27,880 |
| 2017-02-28 | STML | Stemline Therapeutics Inc | Sale | 4,027 | 7.01 | 28,229 |
| 2017-02-16 | STML | Stemline Therapeutics Inc | Sale | 1,508 | 6.42 | 9,681 |
| 2017-01-10 | STML | Stemline Therapeutics Inc | Sale | 9,110 | 13.82 | 125,900 |
| 2016-03-08 | STML | Stemline Therapeutics Inc | Sale | 2,412 | 5.34 | 12,880 |
| 2016-02-17 | STML | Stemline Therapeutics Inc | Sale | 1,503 | 4.54 | 6,823 |
| 2015-03-19 | STML | Stemline Therapeutics Inc | Option Ex | 27,105 | 4.09 | 110,859 |
| 2015-03-19 | STML | Stemline Therapeutics Inc | Sale | 17,307 | 16.43 | 284,354 |
| 2015-02-18 | STML | Stemline Therapeutics Inc | Sale | 1,593 | 14.02 | 22,333 |
| 2014-09-02 | STML | Stemline Therapeutics Inc | Buy | 2,000 | 10.99 | 21,976 |
| 2014-05-21 | STML | Stemline Therapeutics Inc | Sale | 15,250 | 13.32 | 203,130 |
| 2013-11-22 | STML | Stemline Therapeutics Inc | Option Ex | 35,000 | 1.11 | 38,850 |
| 2013-11-22 | STML | Stemline Therapeutics Inc | Sale | 11,523 | 20.14 | 232,073 |
| 2013-11-25 | STML | Stemline Therapeutics Inc | Option Ex | 37,000 | 1.11 | 41,070 |
| 2013-11-26 | STML | Stemline Therapeutics Inc | Option Ex | 6,967 | 1.11 | 7,733 |
| 2013-11-25 | STML | Stemline Therapeutics Inc | Sale | 14,350 | 21.94 | 314,839 |
| 2013-11-27 | STML | Stemline Therapeutics Inc | Option Ex | 33,973 | 1.11 | 37,710 |
| 2013-11-26 | STML | Stemline Therapeutics Inc | Sale | 3,144 | 21.27 | 66,872 |
| 2013-11-27 | STML | Stemline Therapeutics Inc | Sale | 15,411 | 19.91 | 306,833 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hoberman Kenneth (Chief Operating Officer of Stemline Therapeutics Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.